News
ViraDx™ Receives Interim Order Authorization from Health Canada
June 28, 2022Lumos Diagnostics Introduces 15-minute ViraDx™ Test for COVID-19, Flu A and Flu B.
Lumos Diagnostics Appoints Doug Ward As CEO
Ward to lead U.S. FebriDx launch pending FDA 510(k) clearance
Lumos Diagnostics Receives Authorization for CoviDx™ SARS-CoV-2 Rapid Antigen Test in Canada
MELBOURNE, VIC. (03 November 2021): Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that Health Canada has granted Interim Order authorization for the Lumos CoviDx™ SARS-CoV-2 Rapid Antigen Test. The CoviDx test gives qualified … Continued
Box Hill Hospital Emergency Department Initiates Trial Using FebriDx®
MELBOURNE, VIC. (24 October 2021) – Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Emergency Department at Box Hill Hospital in Melbourne, Australia, has initiated a 300-subject investigator-led trial using Lumos’ FebriDx® … Continued
Economic Evaluation of Lumos Diagnostics’ FebriDx® Point-of-Care Test Highlights $2.5 Billion in Potential U.S. Healthcare Cost Savings Annually
SARASOTA, Fla. (October 6, 2021) – Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Journal of Health Economics and Outcomes Research (JHEOR) has published an economic study that concludes using the FebriDx® … Continued
Dr. Jerome Adams, Former U.S. Surgeon General, Joins Lumos Diagnostics as a Strategic Healthcare Adviser
Immediate former U.S. Surgeon General, Jerome Adams, MD, MPH, will join Lumos as a Strategic Healthcare Adviser and will be appointed to the Company’s Medical Advisory Board.
Lumos Diagnostics FY21 Full Year Results
Lumos announced its FY21 full year results including Appendix 4E and Annual Report to Shareholders for the fiscal year ending on 30 June 2021.
Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.
